elcucador
Forumer storico
E SAREBBE PURE ORA VISTO CHE GUADAGNA 50.000 EURO MESE.
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
E SAREBBE PURE ORA VISTO CHE GUADAGNA 50.000 EURO MESE.
viralic
Forumer storico
Nicox and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize NCX 470 in the Chinese market
...............................................
December 17, 2018 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, andOcumension Therapeutics today announced they have entered into an exclusive license agreement for the development and commercialization of Nicox's product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension for a territory comprising mainland China, Hong Kong, Macau and Taiwan. Ocumension Therapeutics is an ophthalmology company funded by 6 Dimensions Capital, one of the leading global healthcare investment funds, formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.
Ocumension will receive exclusive rights to develop and commercialize NCX 470, at its own cost, in the agreed territory. Under the terms of the agreement, Nicox will receive a one-time upfront payment of €3 million from Ocumension and a further €2.5 million when Nicox initiates a Phase 3 clinical study with NCX 470 outside the territory of this agreement. Under this agreement, Nicox is also eligible to receive up to an additional €14.5 million in milestones associated with Ocumension's progress with NCX 470, up to and including regulatory approval, and up to €16.25 million split over three separate sales milestones associated with potential sales in the territory of up to €200 million, as well as tiered royalties from 6% to 12% on sales.
"This collaboration offers Nicox the opportunity to access the fast-growing Chinese ophthalmology market in partnership with an emerging player" said Gavin Spencer, Executive Vice President, Chief Business Officer of Nicox. "Ocumension, which is financed by leading investors, has a strong team, both for development and commercialization, with significant ophthalmology experience and we look forward to developing NCX 470 in the Chinese market with them."
"Ocumension is focused on bringing novel ophthalmic therapeutics to the Chinese market, and so we welcome the opportunity to partner with Nicox, one of the leading R&D companies in the glaucoma space, to develop NCX 470," said Ye Liu, Chief Executive Officer of Ocumension. "We believe the novel NO-donating mechanism of action of NCX 470 offers significant innovation and potential benefits for patients in our region."
Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of NCX 470 in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost.
...............................................
- Accesses the fast-growing Chinese glaucoma market
- Nicox to potentially receive up to €36.25 million in development and commercial milestones payments, including a €3 million upfront payment
- Tiered royalties from 6% to 12% on net sales of NCX 470 in the Chinese market
- Ocumension responsible for all development and commercialization activities in the Chinese market
December 17, 2018 - release at 7:30 am CET
Sophia Antipolis, France
Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, andOcumension Therapeutics today announced they have entered into an exclusive license agreement for the development and commercialization of Nicox's product candidate, NCX 470, targeting patients with glaucoma or ocular hypertension for a territory comprising mainland China, Hong Kong, Macau and Taiwan. Ocumension Therapeutics is an ophthalmology company funded by 6 Dimensions Capital, one of the leading global healthcare investment funds, formed by the merger of Wuxi Healthcare Ventures and Frontline BioVentures.
Ocumension will receive exclusive rights to develop and commercialize NCX 470, at its own cost, in the agreed territory. Under the terms of the agreement, Nicox will receive a one-time upfront payment of €3 million from Ocumension and a further €2.5 million when Nicox initiates a Phase 3 clinical study with NCX 470 outside the territory of this agreement. Under this agreement, Nicox is also eligible to receive up to an additional €14.5 million in milestones associated with Ocumension's progress with NCX 470, up to and including regulatory approval, and up to €16.25 million split over three separate sales milestones associated with potential sales in the territory of up to €200 million, as well as tiered royalties from 6% to 12% on sales.
"This collaboration offers Nicox the opportunity to access the fast-growing Chinese ophthalmology market in partnership with an emerging player" said Gavin Spencer, Executive Vice President, Chief Business Officer of Nicox. "Ocumension, which is financed by leading investors, has a strong team, both for development and commercialization, with significant ophthalmology experience and we look forward to developing NCX 470 in the Chinese market with them."
"Ocumension is focused on bringing novel ophthalmic therapeutics to the Chinese market, and so we welcome the opportunity to partner with Nicox, one of the leading R&D companies in the glaucoma space, to develop NCX 470," said Ye Liu, Chief Executive Officer of Ocumension. "We believe the novel NO-donating mechanism of action of NCX 470 offers significant innovation and potential benefits for patients in our region."
Ocumension is expected to have to conduct additional clinical studies for the regulatory approval of NCX 470 in the Chinese market. All development activities will be overseen by a Joint Development Committee comprising representatives of both companies, with Ocumension responsible for undertaking all the activities at its own cost.
viralic
Forumer storico
600.000 euro all'anno ???......a me risulta 250.000 euro lordi all'anno......informati meglio !!!
PIZZODIGINO
Pacifico
visto che è arrivato il regalo da Babbo Garufi.
La Cina è vicina
La Cina è vicina
elcucador
Forumer storico
serre40
15 déc. 2018•13:20
Depuis des années lui il est bien au chaud avec ces 50 milles euros par mois.
Letto qui su boursorama.
E comunque pure 250.000 sono tanti anche in rapporto ai risultati portati agli azionisti.
non capisco davvero per quale motivo,e parlo in generale,un ceo debba guadagnare 20.000 euro mese,mi domando quali grandi responsabilita' possa avere un ceo per prendere certe cifre visto che in quasi tutti i casi poi se l'azienda fallisce loro non pagano mai.
elcucador
Forumer storico
si ma i 40 sono non lontani,ma lontanissimi.
ora vediamo quantoregge,perche' qui ho ben notato che il ribasso e' stato ben pilotato da chi sa prima le news,e' molto evidente che qualcuno sapeva.
PIZZODIGINO
Pacifico
farmacia10
el pueblo unido...
auguri e buone feste a tutti
sempre forza nicox
ciao
sempre forza nicox
ciao
viralic
Forumer storico
serre40
15 déc. 2018•13:20
Depuis des années lui il est bien au chaud avec ces 50 milles euros par mois.
Letto qui su boursorama.
E comunque pure 250.000 sono tanti anche in rapporto ai risultati portati agli azionisti.
non capisco davvero per quale motivo,e parlo in generale,un ceo debba guadagnare 20.000 euro mese,mi domando quali grandi responsabilita' possa avere un ceo per prendere certe cifre visto che in quasi tutti i casi poi se l'azienda fallisce loro non pagano mai.
Sono lordi.....quindi togli pure il 60% di tasse......i managers tutti sono in questo range di stipendio.....da quelli pubblici a quelli privati. Garufi è nel range basso...credimi....se vai a vedere i managers Molmed siamo ben più in alto, tanto per fare il solito esempio.
Tanti..?....pochi?......è il mercato mondiale che stabilisce lo stipendio dei managers.....così come i governi dei vari paesi decidono lo stipendio dei loro parlamentari....vogliamo parlarne ?.......quelli italiani sono doppi o tripli a quelli tedeschi , francesi o inglesi?.....forse fanno più schifo questi che non i managers delle aziende....almeno loro lo stipendio lo prendono insieme ad una marea di responsabilità....in parlamento c'è chi prende lo stipendio di 13.000 euro mensili per andare a lavorare 7 giorni ( e sono tanti forse) su 30
Ultima modifica:
elcucador
Forumer storico
comunque solito movimento,titolo buono solo per queste operazioni che qualcuno conosce prima.
solita manovra al ribasso e poi la news che fa guadagnare chi sa o puo' sapere.
non cambia niente ai fini della quotazione,sempre li rimane.
in prativca niente di nuovo sul fronte occidentale.
ALTRO CHE REGALO DI GARUFI.
PIZZO SE VUOI IL REGALO TE LO DEVI COMPRARE.
solita manovra al ribasso e poi la news che fa guadagnare chi sa o puo' sapere.
non cambia niente ai fini della quotazione,sempre li rimane.
in prativca niente di nuovo sul fronte occidentale.
ALTRO CHE REGALO DI GARUFI.
PIZZO SE VUOI IL REGALO TE LO DEVI COMPRARE.
